Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$530.39 USD
-5.53 (-1.03%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $530.30 -0.09 (-0.02%) 4:22 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELV 530.39 -5.53(-1.03%)
Will ELV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELV
UnitedHealth (UNH), Amedisys Clear Merger Hurdle With Asset Sale
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
ELV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Elevance Health (ELV) is a Top Value Stock for the Long-Term
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
Humana (HUM) Ties Up With PsychArmor for Better Veteran Care
Other News for ELV
Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2024 Results on July 17, 2024
Morgan Stanley Says Elevance Health's Growth Attributed To Consistent Performance But Undervalued
Tracking Ruane, Cunniff, & Goldfarb's Portfolio - Q1 2024 Update
16 Analysts Have This To Say About Elevance Health